We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DOCU:NASDAQDocuSign, Inc. Analysis

Data as of 2026-03-29 - not real-time

$45.71

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

DocuSign is currently priced at $45.71, which sits below its 20‑day (≈$47.4) and 50‑day (≈$48.6) simple moving averages, indicating a short‑term bearish bias. The stock is trading just above the technical support level of $44.17 and well under the resistance at $51.40, framing a relatively tight range. The 14‑day RSI of 43 points to a neutral‑to‑slightly‑oversold condition, while the MACD histogram has turned positive, hinting at a possible early momentum shift. Volume has been increasing, supporting the notion that buying interest is picking up despite the downtrend. However, the 30‑day realized volatility exceeds 40% and a beta of 1.19 signals that price swings may be amplified relative to the broader market. The Fear & Greed index currently reads “Greed,” suggesting market sentiment is tilted toward risk‑on behavior.
On the fundamentals side, DOCU delivered 7.8% revenue growth to $3.22 B and preserved a robust 79.6% gross margin, translating into a 9.6% net profit margin. Operating cash flow of $1.17 B and free cash flow of $1.20 B underscore strong cash generation, while the balance sheet shows net cash of roughly $680 M after accounting for debt. The forward EPS estimate of $5.05 pulls the forward P/E down to about , markedly below the industry average of 32×, and the DCF‑derived fair value of $118 suggests more than 40% upside. Management has announced an expanded share‑repurchase program, which could further support price appreciation in the absence of a dividend. Analyst consensus remains “hold” with 18 contributors, but the median price target of $60 and mean target of $64.5 indicate expectations of a modest rally. Given the blend of undervaluation, solid profitability, and strategic focus on AI‑driven agreement management, the outlook improves for medium‑ and long‑term investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near technical support
  • positive MACD histogram indicating early momentum
  • high volatility and bearish moving‑average alignment

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair‑value upside of >40% versus current price
  • forward P/E ~9× well below industry average
  • strong cash generation and ongoing share‑repurchase program

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • AI‑powered Intelligent Agreement Management platform expanding TAM
  • high gross margins and recurring revenue model
  • net cash position and low leverage supporting sustainable growth

Key Metrics & Analysis

Financial Health

Revenue Growth7.80%
Profit Margin9.60%
P/E Ratio30.9
ROE15.77%
ROA4.53%
Debt/Equity9.65
P/B Ratio4.7
Op. Cash Flow$1.2B
Free Cash Flow$1.2B
Industry P/E32.0

Technical Analysis

TrendBearish
RSI43.0
Support$44.17
Resistance$51.40
MA 20$47.36
MA 50$48.58
MA 200$66.83
MACDBullish
VolumeIncreasing
Fear & Greed Index65.98

Valuation

Fair Value$117.89
Target Price$64.55
Upside/Downside41.22%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta1.19
Volatility42.09%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.